Precision Nanomedicine

As a global leader in radiochemistry and molecular imaging and member of the Scientific Advisory Board for the AMTAR – housed at AIBN –Professor Jason Lewis, Deputy Director of the Sloan Kettering Institute in New York City, is well positioned to comment on the dramatic rise of radiopharmaceuticals over the last decade.

A collaboration between AIBN’s Associate Professor Shyuan Ngo's MND-focused lab and Shiga University in Japan has found that lactate is a biomarker for ALS

A team at AIBN has developed a world-first assay that rapidly measures interactions between tiny particles in the bloodstream - a crucial step in understanding how diseases like cancer develop and spread.

New research from the AIBN has revealed that neurons in the brain use fats for energy, challenging decades of scientific thinking and opening the door to new treatments for neurological disease.

Sponge-like gold particles could be used to triage women with suspected ovarian cancer more accurately than current diagnostic tools, addressing one of the leading causes of cancer death in women, which claims more than 1,000 lives in Australia each year.

A new clinical trial gets the green light as researchers from UQ’s Australian Institute for Bioengineering and Nanotechnology (AIBN) investigate whether a common heart medication could help treat people living with the form of motor neurone disease known as Amyotrophic Lateral Sclerosis (ALS).

Growing up, Dr Laura Leighton was always the curious kid. The pre-schooler who raised tadpoles in a backyard pool and asked big questions about how life worked. That early curiosity never left.

Associate Professor Shyuan Ngo, or "Shu" as she is widely known, has been walking the halls of UQ since 1999. She first arrived as an undergraduate student and is now a group leader at the AIBN, where she leads research into MND.

A team of researchers at the AIBN, led by Dr Ruirui Qiao, have successfully patented a breakthrough tool accelerating this research and bringing regenerative medicine solutions closer to reality.

A novel cutting-edge technology is accelerating the development of next-generation cancer treatments, with AIBN now home to an AdvanCell Lead-212 generator.